Lv1
20 积分 2023-08-23 加入
为高质量的临床试验而奋斗，为改变临床实践而奋斗，为医药进步和患者健康而奋斗~
Design Strategy and Consideration for Oncology Dose-Optimization: An Industry Perspective
6天前
已完结
Optimal Biomarker Cutoff Identification and Validation
1个月前
已完结
Glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide receptor co-agonists for cardioprotection, type 2 diabetes and obesity: a review of mechanisms and clinical data
2个月前
已完结
Current strategies for targeting HPK1 in cancer and the barriers to preclinical progress
3个月前
已完结
High HPK1+PD-1+TIM-3+CD8+ T cells infiltration predicts poor prognosis to immunotherapy in NSCLC patients
4个月前
已完结
Ocular toxicities of fibroblast growth factor receptor inhibitors: A review
4个月前
已完结
The HPK1 Inhibitor A-745 Verifies the Potential of Modulating T Cell Kinase Signaling for Immunotherapy
5个月前
已完结
Computational analysis of cancer genome sequencing data
5个月前
已完结
FDA Approval Summary: Mirvetuximab Soravtansine-Gynx for FRα-Positive, Platinum-Resistant Ovarian Cancer
7个月前
已完结
Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial
9个月前
已完结
皖公网安备34019202002308
